tiprankstipranks
eFFECTOR Therapeutics trading resumes
PremiumThe FlyeFFECTOR Therapeutics trading resumes
9M ago
eFfector sees no ‘obvious’ path forward for tomivosertib development in NSCLC
Premium
The Fly
eFfector sees no ‘obvious’ path forward for tomivosertib development in NSCLC
9M ago
eFFECTOR Therapeutics trading halted, news pending
Premium
The Fly
eFFECTOR Therapeutics trading halted, news pending
9M ago
eFFECTOR Therapeutics Regains Nasdaq Compliance Status
PremiumCompany AnnouncementseFFECTOR Therapeutics Regains Nasdaq Compliance Status
12M ago
eFFECTOR Therapeutics Secures $15M in Direct Offering
Premium
Market News
eFFECTOR Therapeutics Secures $15M in Direct Offering
12M ago
eFfector to sell 1.49M shares at $10.075 in registered direct offering
Premium
The Fly
eFfector to sell 1.49M shares at $10.075 in registered direct offering
12M ago
eFfector Therapeutics board approves 1-for-25 reverse stock split
PremiumThe FlyeFfector Therapeutics board approves 1-for-25 reverse stock split
1y ago
eFfector announces interim data from Phase 2 expansion cohorts of zotatifin
Premium
The Fly
eFfector announces interim data from Phase 2 expansion cohorts of zotatifin
1y ago
eFFECTOR Therapeutics receives Fast Track Designation for zotatifin combination
Premium
The Fly
eFFECTOR Therapeutics receives Fast Track Designation for zotatifin combination
1y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100